Emily Schirmer
Dr. Schirmer has over 15 years of experience in the bioprocess development and manufacturing industry. She joined Catalent in 2015 and is responsible for Upstream and Downstream Process Development, Analytical Development, and Manufacturing Sciences and Technology. Her team is responsible for the full spectrum of biologics process development including clinical and commercial processes for a multimodal portfolio. Before joining Catalent, Dr. Schirmer worked at Illumina, where she created capabilities to scale and optimize enzyme production processes to support Illumina’s portfolio of DNA sequencing technology. Prior to this, she worked at startup companies in Cambridge, MA, developing and transferring processes for the clinical manufacture of antibodies and recombinant proteins. Dr. Schirmer received her BChE from the University of Delaware and her MS and PhD in Chemical Engineering from the University of Virginia.